Generation Bio Co (GBIO NASDAQ) stock market data APIs
$0.3666
0.01(2.7%)
as of June 13, 2025
Try our APIs with
free plan!
Generation Bio Co Financial Data Overview
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Prev. Close
0.3666
Open
0.3814
High
0.3867
Low
0.365
52 wk Range
0.316-3.65
Market Cap
25 674 K
Shares Outstanding
67 035 K
Revenue
24 556 K
EPS
-0.2039
Beta
2.662
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Generation Bio Co data using free add-ons & libraries
Get Generation Bio Co Fundamental Data
Generation Bio Co Fundamental data includes:
- Net Revenue: 24 556 K
- EBITDA: -69 202 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Generation Bio Co News
New
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune disea...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash ba...
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Generation Bio Co. CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent ...
Charles Rowland Bought 179% More Shares In Generation Bio
Potential Generation Bio Co. (NASDAQ:GBIO) shareholders may wish to note that the Independent Director, Charles Rowland, recently bought US$478k worth of stock, paying US$1.39 for each share. We recko...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
